Gilead Sciences (NQ:GILD)

144.63 -0.11 (-0.08%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

78 79 Next >

These 2 Dividend Stocks Are Absolute Bargains Right Now ↗

February 08, 2025

Via The Motley Fool

Top Analyst Reports For Uber, Comcast & Gilead ↗

February 07, 2025

Today's Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc., Comcast Corp, and Gilead Sciences, Inc., as well as a micro-cap stock Onfolio Holdings, Inc.

Via Talk Markets

Topics Stocks / Equities

3 Top AI-Powered Biotech Stocks to Buy in February ↗

February 06, 2025

Via The Motley Fool

Salesforce Names Board Member As Software Maker's New CFO And COO ↗

February 06, 2025

The Dow software giant named Robin Washington, as its new CFO and COO.

Via Investor's Business Daily

Topics Stocks

Can Biotech Stocks Survive The Precarious Macro? ↗

February 03, 2025

We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

Via Talk Markets

Topics Stocks / Equities World Trade

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

January 31, 2025

Via Benzinga

Looking At Gilead Sciences's Recent Unusual Options Activity ↗

January 29, 2025

Via Benzinga

Breaking Down Gilead Sciences: 22 Analysts Share Their Views ↗

January 29, 2025

Via Benzinga

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗

January 31, 2025

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Via Benzinga

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

January 28, 2025

From Gilead Sciences, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

January 27, 2025

Via Benzinga

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

Looking Into Gilead Sciences's Recent Short Interest ↗

January 07, 2025

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗

January 06, 2025

Via Benzinga

(GILD) - Analyzing Gilead Sciences's Short Interest ↗

December 19, 2024

Via Benzinga

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

Is GILEAD SCIENCES INC Ready to Break Out of Its Range? ↗

December 19, 2024

In-Depth Technical Analysis of GILEAD SCIENCES INC.

Via Chartmill

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? ↗

January 17, 2025

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Via Stocktwits

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

January 11, 2025

From Gilead Sciences, Inc.

Via Business Wire

This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

January 10, 2025

Via Benzinga

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus ↗

January 08, 2025

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.

Via Benzinga

Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday ↗

December 31, 2024

Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought.

Via Benzinga

Healthcare And Biotech Stocks Continue Their Slide ↗

December 30, 2024

Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December.

Via Talk Markets

Topics ETFs Stocks / Equities

Based on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout. ↗

December 25, 2024

GILEAD SCIENCES INC (NASDAQ:GILD) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

Via Chartmill

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

Gilead Sciences to Present at Upcoming Investor Conference

December 20, 2024

From Gilead Sciences, Inc.

Via Business Wire

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

COVID-19 is Not the Same Disease for Everyone

December 20, 2024

(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated...

Via Brandpoint

Topics Death

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

December 17, 2024

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.